Article

Ohr completes wet-AMD trial enrollment

Ohr Pharmaceuticals has completed the enrollment of its OHR-022 phase II clinical trial evaluating its treatment of we age-related macular degeneration (AMD), Squalamine eye drops.

 

New York-Ohr Pharmaceutical has completed the enrollment of its OHR-002 phase II clinical trial evaluating its treatment of wet age-related macular degeneration (AMD), Squalamine eye drops.

The study has enrolled 142 patients, and the company expects to announce interim data on the first 60 patients completing the protocol in June. Final data are expected in the first calendar quarter of 2015.

“I am pleased with the continued progress of this important study and look forward to the upcoming panned interim analysis,” said Jeffrey S. Heier, MD, director of the vitreoretinal service at Ophthalmic Consultants of Boston, and member of Ohr’s scientific advisory board. “A topical therapeutic would offer an important alternative for the large wet AMD patient population currently being treated with frequent intravitreal injections.”

“We are very encouraged by the interest shown by both patients and physicians in this trial and believe our eye drop formulation . . . has the potential to be a valuable new treatment for wet AMD,” said Irach B. Taraporewala, PhD, chief executive officer of Ohr.

 

 

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.